The early history and development of thrombolysis in acute myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 1867-1870

  Maroo, A ^a   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; LANETOPLASE; PLASMINOGEN ACTIVATOR DERIVATIVE; RETEPLASE; STREPTOKINASE; TENECTAPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CORONARY ARTERY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MONITORING; DRUG SYNTHESIS; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE NECROSIS; HUMAN; HYPOTHESIS; IN VIVO STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOSIS;

CARRIER PROTEINS; CORONARY THROMBOSIS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; THROMBOLYTIC THERAPY;

EID: 13244262632     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00881.x     Document Type: Article

References (22)

1. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556-85.
2. Acierno LJ. The History of Cardiology. New York: The Parthenon Publishing Group; 1994.
3. Osler W. The Principle and Practice of Medicine. New York: D. Appleton; 1892.
4. Muller JE. Diagnosis of myocardial infarction: historical notes from the Soviet Union and the United States. Am J Cardiol 1977; 40: 269-71.
5. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59: 2015-20.
6. Friedberg CK, Horn H. Acute myocardial infarction not due to coronary artery occlusion. JAMA 1939; 112: 1675-9.
7. Miller RD, Burchell HB, Edwards JE. Myocardial infarction with and without acute coronary occlusion. Arch Intern Med 1951; 88: 597-604.
8. Roberts WC, Ferrans VJ. The role of thrombosis in the etiology of atherosclerosis (a positive one) and in precipitating fatal ischemic heart disease (a negative one). Semin Thromb Hemost 1976; 2: 123-35.
9. DeWood M, Spores J, Notske R, Mouser L, Burroughs R, Golden M, Lang H. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 898-902.
10. Tillet W, Garner R. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
11. Sherry S, Tillet WS, Read CT. The use of stretokinase-streptodornase in the treatment of hemothorax. J Thorac Surg 1950; 20: 393-418.
12. Tillet W, Sherry S, Read C. The use of streptokinase-streptodornase in the treatment of chronic empyema. J Thorac Surg 1951; 21: 325-41.
13. Sherry S, Fletcher A, Alkjaersigm N, Smyrniotis F. An approach to intravascular fibrinolysis in man. Trans Assoc Am Physicians 1957; 70: 288-96.
14. Maroko P, Libby P, Ginks W, Bloor C, Shell W, Sobel B, Ross JJ. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 1972; 51: 2710-6.
15. Sobel BE, Bresnahan GF, Shell WE, Yoder RD. Estimation of infarct size in man and its relation to prognosis. Circulation 1972; 46: 640-8.
16. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter Arkh 1976; 48: 8-19.
17. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H, Oster H, Leitz K. Acute myocardial infarction. intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2: 354-63.
18. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 8478: 397-402.
19. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-41.
20. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984; 310: 609-13.
21. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robinson AI, Hutter AM Jr, Bell WR, Spadaro JJ Jr, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-7.
22. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-82.